RESEARCHER PROFILE

David James Pinato

← Back to Imperial College London

D

Imperial College London

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesMetabolism, Diabetes, and CancerInflammatory Biomarkers in Disease Prognosis

David James Pinato works in Cancer Immunotherapy and Biomarkers, Hepatocellular Carcinoma Treatment and Prognosis, Colorectal Cancer Treatments and Studies, Metabolism, Diabetes, and Cancer, Inflammatory Biomarkers in Disease Prognosis. Recorded institutional associations include Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Hammersmith Hospital, Imperial College London.

920Publications
19,110Citations
70H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Immunotherapies for hepatocellular carcinoma

    2021 · 1,816 citations
  2. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    2021 · 1,280 citations
  3. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

    2019 · 620 citations
  4. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)

    2012 · 421 citations
  5. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma

    2016 · 413 citations
  6. PD-L1

    2017 · 317 citations
  7. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

    2021 · 303 citations
  8. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

    2020 · 272 citations
  9. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy

    2020 · 248 citations
  10. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

    2022 · 235 citations
  11. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.

    2021 · 224 citations
  12. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma

    2021 · 219 citations
  13. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

    2023 · 206 citations
  14. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

    2019 · 204 citations
  15. Immune-based therapies for hepatocellular carcinoma

    2020 · 202 citations
  16. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma

    2022 · 186 citations
  17. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

    2020 · 182 citations
  18. A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI)

    2012 · 181 citations
  19. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

    2020 · 179 citations
  20. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

    2021 · 164 citations
  21. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

    2021 · 160 citations
  22. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer

    2014 · 156 citations
  23. Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis

    2019 · 150 citations
  24. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

    2021 · 150 citations
  25. Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma

    2012 · 147 citations

← Return to the university profile